421 related articles for article (PubMed ID: 16304147)
21. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.
Raad II; Hanna HA; Boktour M; Jiang Y; Torres HA; Afif C; Kontoyiannis DP; Hachem RY
Leukemia; 2008 Mar; 22(3):496-503. PubMed ID: 18094720
[TBL] [Abstract][Full Text] [Related]
22. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
Moen MD; Lyseng-Williamson KA; Scott LJ
Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
[TBL] [Abstract][Full Text] [Related]
23. Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin.
Graybill JR; Bocanegra R; Gonzalez GM; Najvar LK
J Antimicrob Chemother; 2003 Oct; 52(4):656-62. PubMed ID: 12972452
[TBL] [Abstract][Full Text] [Related]
24. Retinal function assessed by ERG before and after induction of ocular aspergillosis and treatment by the anti-fungal, micafungin, in rabbits.
Harrison JM; Glickman RD; Ballentine CS; Trigo Y; Pena MA; Kurian P; Najvar LK; Kumar N; Patel AH; Sponsel WE; Graybill JR; Lloyd WC; Miller MM; Paris G; Trujillo F; Miller A; Melendez R
Doc Ophthalmol; 2005 Jan; 110(1):37-55. PubMed ID: 16249956
[TBL] [Abstract][Full Text] [Related]
25. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.
Olson JA; Adler-Moore JP; Schwartz J; Jensen GM; Proffitt RT
Antimicrob Agents Chemother; 2006 Jun; 50(6):2122-31. PubMed ID: 16723574
[TBL] [Abstract][Full Text] [Related]
26. CNS-aspergillosis: are there new treatment options?
Schwartz S; Thiel E
Mycoses; 2003; 46 Suppl 2():8-14. PubMed ID: 15055138
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of micafungin alone or in combination against systemic murine aspergillosis.
Luque JC; Clemons KV; Stevens DA
Antimicrob Agents Chemother; 2003 Apr; 47(4):1452-5. PubMed ID: 12654692
[TBL] [Abstract][Full Text] [Related]
28. Disseminated invasive aspergillosis in a patient with acute leukaemia.
Gottfredsson M; Steingrímsdóttir H
Acta Biomed; 2006; 77 Suppl 2():10-3. PubMed ID: 16918060
[TBL] [Abstract][Full Text] [Related]
29. Triple antifungal therapy for the treatment of invasive aspergillosis in a neutropenic pediatric patient.
Sims-McCallum RP
Am J Health Syst Pharm; 2003 Nov; 60(22):2352-6. PubMed ID: 14652986
[No Abstract] [Full Text] [Related]
30. Combination antifungal therapy for invasive aspergillosis: utilizing new targeting strategies.
Steinbach WJ
Curr Drug Targets Infect Disord; 2005 Sep; 5(3):203-10. PubMed ID: 16181140
[TBL] [Abstract][Full Text] [Related]
31. In vitro combined activity of amphotericin B, caspofungin and voriconazole against clinical isolates of Trichosporon asahii.
Li H; Lu Q; Wan Z; Zhang J
Int J Antimicrob Agents; 2010 Jun; 35(6):550-2. PubMed ID: 20202797
[TBL] [Abstract][Full Text] [Related]
32. Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease.
Dennis CG; Greco WR; Brun Y; Youn R; Slocum HK; Bernacki RJ; Lewis R; Wiederhold N; Holland SM; Petraitiene R; Walsh TJ; Segal BH
Antimicrob Agents Chemother; 2006 Feb; 50(2):422-7. PubMed ID: 16436692
[TBL] [Abstract][Full Text] [Related]
33. [symbol: see text]Caspofungin and [symbol: see text]voriconazole for fungal infections.
Drug Ther Bull; 2004 Jan; 42(1):5-8. PubMed ID: 14768298
[TBL] [Abstract][Full Text] [Related]
34. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study.
Singh N; Limaye AP; Forrest G; Safdar N; Muñoz P; Pursell K; Houston S; Rosso F; Montoya JG; Patton P; Del Busto R; Aguado JM; Fisher RA; Klintmalm GB; Miller R; Wagener MM; Lewis RE; Kontoyiannis DP; Husain S
Transplantation; 2006 Feb; 81(3):320-6. PubMed ID: 16477215
[TBL] [Abstract][Full Text] [Related]
35. An update on the use of antifungal agents.
Martinez R
J Bras Pneumol; 2006; 32(5):449-60. PubMed ID: 17268750
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of posaconazole in a murine model of central nervous system aspergillosis.
Imai JK; Singh G; Clemons KV; Stevens DA
Antimicrob Agents Chemother; 2004 Oct; 48(10):4063-6. PubMed ID: 15388482
[TBL] [Abstract][Full Text] [Related]
37. Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infections.
Olson JA; George A; Constable D; Smith P; Proffitt RT; Adler-Moore JP
Antimicrob Agents Chemother; 2010 Sep; 54(9):3884-94. PubMed ID: 20606065
[TBL] [Abstract][Full Text] [Related]
38. Combination antifungal therapy for invasive aspergillosis.
Marr KA; Boeckh M; Carter RA; Kim HW; Corey L
Clin Infect Dis; 2004 Sep; 39(6):797-802. PubMed ID: 15472810
[TBL] [Abstract][Full Text] [Related]
39. Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging.
Galiger C; Brock M; Jouvion G; Savers A; Parlato M; Ibrahim-Granet O
Antimicrob Agents Chemother; 2013 Jul; 57(7):3046-59. PubMed ID: 23587947
[TBL] [Abstract][Full Text] [Related]
40. Combination antifungal therapy for invasive aspergillosis.
Cesaro S; Visintin G
Clin Infect Dis; 2005 Apr; 40(7):1073-5; author reply 1075-6. PubMed ID: 15825015
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
